This page shows what was measured, who it was measured in, and what that does not settle.
What Lanreotide does in the body
Unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tu
From the FDA-approved label: Lanreotide, the active component of Lanreotide Injection, is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 0G3DE8943Y · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 59 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Phase 1b: RP3D
✗ The study did not show it
Who was studied
NCT05477576
How many people
338
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
✗ The study did not show it
Who was studied
NCT05050942
How many people
332
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change in renal function
✗ The study did not show it
Who was studied
NCT01616927
How many people
300
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
What a body can do day to day
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Incidence of postoperative pancreatic fistula (POPF)
✗ The study did not show it
Who was studied
NCT06807437
How many people
274
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy
✗ The study did not show it
Who was studied
NCT05701241
How many people
270
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT00353496
How many people
264
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.4 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
plasma concentration of debio 4126 in acromegaly and gep net
Meaningful
Things that change how a life goes, not only a number.
time to disease progression
progression free survival
prolongation of the survival curve
clinical outcome overall survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (13)
adverse events
responder
liver volume
cost effectiveness
renal function
glomerular filtration rate
incidence of adverse events
bowel movements
objective response rate
primary safety endpoint
phase 1b rp3d
phase 3 pfs as determined by bicr
incidence of postoperative pancreatic fistula
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 23 to 30 days
Read from the label, which states: “Lanreotide showed sustained release of lanreotide with a half-life of 23 to 30 days.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of Lanreotide Injection in pediatric patients have not been established.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
On older people, the label states: “No overall differences in safety or effectiveness were observed between elderly patients with acromegaly compared with younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Limited available data based on post-marketing case reports with lanreotide use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information available on the presence of lanreotide in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
On people with reduced liver function, the label states: “Acromegaly It is recommended that patients with moderate or severe hepatic impairment receive a starting dose of Lanreotide Injection 60 mg.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
On people with reduced kidney function, the label states: “Acromegaly Lanreotide has been studied in patients with end-stage renal function on dialysis, but has not been studied in patients with mild, moderate, or severe renal impairment.”
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1.
No source is stored against this line.
What is in the pack
Sold as solution, injection, given by the subcutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Lanreotide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1833 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
diarrhoea — 401 reaction mentions
nausea — 236 reaction mentions
fatigue — 202 reaction mentions
injection site pain — 192 reaction mentions
abdominal pain — 168 reaction mentions
headache — 159 reaction mentions
vomiting — 128 reaction mentions
dizziness — 123 reaction mentions
malaise — 116 reaction mentions
asthenia — 108 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
23 products list this as an active ingredient in the United States drug directory. 23 of them contain it and nothing else.
FDA National Drug Code directory · 71161-116 · read 2026-08-29
They are sold as injection and powder, taken subcutaneous.
FDA National Drug Code directory · 71161-116 · read 2026-08-29
The regulator's established pharmacologic class for it is somatostatin analog [epc] and somatostatin receptor agonists [moa].
FDA National Drug Code directory · 71161-116 · read 2026-08-29
4 published labels name it as an active ingredient. 4 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-29
Lanreotide Acetate is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL of lanreotide in single-dose, prefilled syringes packaged with a safety needle., recorded as fda label in effect 2024-09-01 in the United States.
US prescribing information · 11da176a-99bc-4ada-8b3f-6bd2b37a6313 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Lanreotide studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Lanreotide are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
4 documents were read for this substance.
RNAWiki source record
4 of them state the same halfLife, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
0G3DE8943Y
CAS registry number
108736-35-2
PubChem compound
6918011
ChEMBL
CHEMBL1201185
WHO international nonproprietary name list entry
6649
RxNorm concept
68092
EMA substance identifier
100000082556
DrugBank
DB06791
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
3 approved applications cover products containing this substance. The earliest was NDA022074, approved 20070830 to IPSEN PHARMA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (12)
Q2
What did Lanreotide's largest trial (1965 people) and its longest (33 years) measure?
1965 people in Lanreotide's largest registered study, 33 years in its longest registered window, measuring Prolongation of the survival curve (>6 months). ClinicalTrials.gov · 2026-09-01
23 phase2, 20 phase3, 8 phase4, 4 phase1, 3 na or unstated, 1 na; NCT03158090; 2051-01-30; no ageing endpoint recorded. Last human test completed 2023, NCT02795858.
Interpretation These counts include studies where Lanreotide was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
23
phase3
20
phase4
8
phase1
4
na or unstated
3
na
1
1 more recorded row
Last recorded human testNCT02795858
2023-12-31
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Lanreotide shown lifespan?
"Administrative reasons"; 9 of 50 registered studies
Show the evidence
Trial
NCT00517491
withdrawn; "Administrative reasons"
NCT01538966
terminated; "Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB…"
NCT01861717
terminated; "Didn't enroll enough subjects"
NCT02288377
terminated; "Because of slow recruitment"
NCT02365584
terminated; "The study was terminated early due to insufficient recruitment."
NCT02683941
terminated; "National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment."
3 further recorded trials
NCT02859064
terminated; "Closed due to slow accrual"
NCT04065165
withdrawn; "Company decision"
NCT05364944
terminated; "The recruitment was halted for strategic reasons"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Lanreotide's half-life is 23 to 30 days — which schedules were studied?
23 to 30 days, the half-life Lanreotide's label states. openfda-label · 2892b4c3-0329-4d29-97ff-3b45283bbab1 · 2026-08-30
Show the evidence
half life
23 to 30 days; Lanreotide showed sustained release of lanreotide with a half-life of 23 to 30 days.
bioavailability
After a single, deep subcutaneous administration, the mean absolute bioavailability of Lanreotide acetate in healthy subjects was 73.4, 69.0, and 78.4% for the 60 mg, 90 mg, and 120 mg doses, respectively.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Which of adverse events, bowel movements and clinical outcome overall survival did Lanreotide's trials measure?
adverse events, bowel movements and clinical outcome overall survival lead 18 outcome terms across Lanreotide's trials. ClinicalTrials.gov · 2026-09-01
Interpretation adverse events, responder, liver volume, cost effectiveness, renal function and glomerular filtration rate follow.
Show the evidence
time to disease progression
1
progression free survival
1
prolongation of the survival curve
1
adverse events
1
responder
1
liver volume
1
12 more recorded rows
cost effectiveness
1
renal function
1
glomerular filtration rate
1
clinical outcome overall survival
1
incidence of adverse events
1
bowel movements
1
objective response rate
1
primary safety endpoint
1
plasma concentration of debio 4126 in acromegaly and gep net
1
phase 1b rp3d
1
phase 3 pfs as determined by bicr
1
incidence of postoperative pancreatic fistula
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Lanreotide's 6 ongoing trials reports first?
clinical outcome: overall survival; Rate of tumor growth; latest 2051-01-30
Show the evidence
Trial
NCT03158090
"The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research"; n 1965; "clinical outcome: overall survival"; 2051-01-30
NCT03946527
"LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)"; n 10; "Rate of tumor growth"; 2027-03
NCT05048901
"Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors"; n 49; "to determine the maximal tolerated dose of cabozantinib"; 2027-12-31
NCT05477576
"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy"; n 338; "Phase 1b: RP3D"; 2030-12
NCT05701241
"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients"; n 270; "the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy"; 2034-04
NCT06807437
"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula"; n 274; "Incidence of postoperative pancreatic fistula (POPF)"; 2027-11-01
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Lanreotide could settle lifespan?
NCT05701241 measures the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy, reading out 2034-04.
2 open trials; n 270; "Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients"
Show the evidence
Trial
NCT05701241
"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients"; n 270; "the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy"; 2034-04
NCT03158090
"The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research"; n 1965; "clinical outcome: overall survival"; 2051-01-30
Q9
Which 14 trials of Lanreotide posted no result?
Posted no result
14 of 14 completed trials
Registrations
NCT00210457, NCT00234572, NCT00149188, NCT00216398, NCT00216372 and NCT00495846, and 8 more
Completion dates
oldest 2002-07-15; newest 2022-07-07
Show the evidence
Trial
NCT00210457
2002-07-15
NCT00234572
2003-01-03
NCT00149188
2005-08-24
NCT00216398
2006-06-22
NCT00216372
2008-10
NCT00495846
2008-12
8 further recorded trials
NCT00326469
2009-11
NCT01076803
2013-07
NCT01354405
2014-06
NCT01070758
2015-02
NCT02351128
2017-05-15
NCT02127437
2019-07-31
NCT02973204
2020-01-08
NCT03967249
2022-07-07
Q10
At the median, Lanreotide's trials enrolled 43.5 people — anything larger?
Median enrolment
43.5
Largest enrolment
1965
Registered trials counted
50
Q11
What do 1833 spontaneous reports say about Lanreotide — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Lanreotide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1833 reaction mentions were counted: diarrhoea 401; nausea 236; fatigue 202; injection site pain 192. open-targets-adr · CHEMBL1201184 · 2026-06-24
Show the evidence
diarrhoea
401
nausea
236
fatigue
202
injection site pain
192
abdominal pain
168
headache
159
4 more recorded rows
vomiting
128
dizziness
123
malaise
116
asthenia
108
recorded 2026-06-24 · last checked 2026-09-04
Q12
Lanreotide and CYP3A4 and cytochrome P450: shared by which compounds?
CYP3A4 and cytochrome P450 appear in Lanreotide's recorded interaction sentences, 2 in all. openfda-label+europepmc · 2025-02-01
Interpretation drug_interactions
Show the evidence
cytochrome P450drug_interactions
7.5 Drug Metabolism Interactions The limited published data available indicate that somatostatin analogs may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of growth hormone.
CYP3A4drug_interactions
Since it cannot be excluded that Lanreotide Injection may have this effect, avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine).
recorded 2025-02-01 · last checked 2026-09-04
Q13
What is recorded about Lanreotide and IGF-1?
"Through IVF and near-normalization of IGF-1 using lanreotide, pregnancy was achieved in a patient with MAS who had achieved good ovarian stimulation despite a history of bilateral ovarian involvement and associated hyperfunctioning endocrinopathies." — where Lanreotide and IGF-1 appear together. Europe PMC · pathway abstract search · 2024-08-15
IGF-1, mTOR; PMID 39781076, 38375032, 38649498
Show the evidence
IGF-1PMID 39781076
"Through IVF and near-normalization of IGF-1 using lanreotide, pregnancy was achieved in a patient with MAS who had achieved good ovarian stimulation despite a history of bilateral ovarian involvement and associated hyperfunctioning endocrinopathies."
mTOR
PMID 38375032
"We focused on assessing whether pretreating cells with inhibitors for phosphatidylinositol 3-kinase (PI3K) and mammalian target for rapamycin (mTOR) could enhance the antiproliferative effects of lanreotide. <b>Methods:</b> BP-NET cell lines NCI-H720 and NCI-H727 were treated with PI3K inhibitor BYL719 (alpelisib), mTOR inhibitor everolimus and SSA lanreotide to determine the effect on NET…"
PMID 38649498
"Major advances have been made in drug therapy, with somatostatin analogs (octreotide and lanreotide), an mTOR inhibitor (everolimus), and a tyrosine kinase inhibitor (sunitinib) being widely used."
recorded 2024-08-15 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 9 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.